Nuvectis Pharma, Inc. (NASDAQ:NVCT) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) have received an average recommendation of “Moderate Buy” from the five analysts that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $36.25.

A number of brokerages have commented on NVCT. HC Wainwright raised their price objective on Nuvectis Pharma from $13.00 to $39.00 and gave the stock a “buy” rating in a research report on Monday, June 22nd. Roth Capital upped their target price on Nuvectis Pharma from $20.00 to $33.00 and gave the company a “buy” rating in a report on Monday, July 6th. Loop Capital set a $40.00 price target on shares of Nuvectis Pharma in a research report on Tuesday. UBS Group set a $33.00 price target on shares of Nuvectis Pharma in a report on Monday, July 6th. Finally, Lucid Cap Mkts raised shares of Nuvectis Pharma to a “strong-buy” rating in a research report on Tuesday.

Nuvectis Pharma Price Performance

NASDAQ:NVCT opened at $24.37 on Friday. The business’s 50-day moving average is $20.89 and its two-hundred day moving average is $13.76. The firm has a market capitalization of $795.44 million, a PE ratio of -18.60 and a beta of -0.26. Nuvectis Pharma has a 12 month low of $5.55 and a 12 month high of $29.27.

Nuvectis Pharma (NASDAQ:NVCT) last released its earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). Equities analysts anticipate that Nuvectis Pharma will post -1.01 EPS for the current year.

Insider Transactions at Nuvectis Pharma

In other news, CEO Ron Bentsur bought 12,500 shares of the stock in a transaction on Tuesday, June 30th. The shares were purchased at an average price of $20.00 per share, for a total transaction of $250,000.00. Following the completion of the purchase, the chief executive officer directly owned 3,688,424 shares of the company’s stock, valued at $73,768,480. This trade represents a 0.34% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Marlio Charles Mosseri purchased 50,000 shares of the business’s stock in a transaction dated Tuesday, June 30th. The shares were purchased at an average cost of $18.32 per share, with a total value of $916,000.00. Following the completion of the purchase, the insider directly owned 3,186,576 shares in the company, valued at approximately $58,378,072.32. This represents a 1.59% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 28.55% of the company’s stock.

Institutional Investors Weigh In On Nuvectis Pharma

A number of large investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System raised its position in shares of Nuvectis Pharma by 376.8% in the second quarter. California State Teachers Retirement System now owns 3,991 shares of the company’s stock valued at $73,000 after purchasing an additional 3,154 shares during the period. Alyeska Investment Group L.P. bought a new position in Nuvectis Pharma in the 2nd quarter worth $5,057,000. Stonepine Capital Management LLC acquired a new position in Nuvectis Pharma during the 2nd quarter worth $735,600. Bank of America Corp DE bought a new stake in Nuvectis Pharma during the second quarter valued at about $218,000. Finally, Legal & General Group Plc bought a new position in shares of Nuvectis Pharma in the second quarter worth about $31,000. Institutional investors own 96.77% of the company’s stock.

Nuvectis Pharma Company Profile

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.